Palbociclib cost?

What is the list price of palbociclib in the United States?
Palbociclib (brand name Ibrance) is listed at roughly $20,000 per month, or about $240,000 for a one‑year course of treatment [1].

How much does insurance usually cover?
Most commercial insurers negotiate discounts with the manufacturer and pharmacy benefit managers. After these reductions, the typical copayment for a patient can drop to a few hundred dollars a month, though exact amounts vary by plan and region.

What is the average out‑of‑pocket cost for a patient?
Depending on coverage, patients often pay between $0 and $1,000 per month for palbociclib. In plans without coverage, the cost can climb to the full list price.

Is a generic version likely to appear soon, and how will that change the price?
The patents covering palbociclib are set to expire in 2028. Once a generic is approved, the price is expected to fall by 60‑70 % or more, potentially bringing the monthly cost to around $6,000–$8,000.

How does palbociclib compare to other CDK4/6 inhibitors?
All three major agents—palbociclib, ribociclib, and abemaciclib—carry similar high list prices (approximately $20,000/month). Generic competition will likely affect each drug in a comparable way once their patents lapse.

Are there discount or patient‑assistance programs?
Yes. The manufacturer runs a patient assistance program that can reduce or waive copayments for uninsured or underinsured patients. Many pharmacies also offer discount cards that lower the price by 10–30 %.

What are the long‑term cost implications for oncology practice?
If a generic palbociclib enters the market, oncology practices may see a significant drop in drug acquisition costs, allowing more patients to access therapy. Until then, high prices remain a major consideration for treatment planning and reimbursement.

Sources
[1] DrugPatentWatch.com – Palbociclib pricing data.